Innovative Medicine Backed by the Power of
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug identification and development
Neuroscience
Immuno-Oncology
Jan 11, 2023
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate CancerVIEW RELEASE
Dec 22, 2022
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceVIEW RELEASE
Dec 19, 2022
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s DiseaseVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Feb 01, 2023 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
29.48
CHANGE
0.96 (3.37%)
